Phase II study of bortezomib and thalidomide in patients with metastatic renal cell carcinoma (MRCC).

被引：0
|
作者：
Amato, R
Misellati, A
Marsh, L
Shen, S
Jac, J
Ross, J
机构：
[1] Methodist Hosp, Res Inst, Houston, TX 77030 USA
[2] Albany Med Coll, Albany, NY 12208 USA
来源：
CLINICAL CANCER RESEARCH | 2005年 / 11卷 / 24期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：9121S / 9122S
页数：2
相关论文
共 50 条
  • [1] ORAL THALIDOMIDE IN PROGRESSING METASTATIC RENAL CELL CARCINOMA (MRCC): A PROSPECTIVE PHASE II STUDY
    Caserta, Claudia
    Bracarda, Sergio
    Ludovini, Vienna
    Darwish, Samir
    Pistola, Lorenza
    Tofanetti, Francesca M.
    Marrocolo, Francesca
    Tonato, Maurizio
    [J]. ANNALS OF ONCOLOGY, 2004, 15 : 91 - 92
  • [2] A phase II study of thalidomide in advanced metastatic renal cell carcinoma
    Minor, DR
    Monroe, D
    Damico, LA
    Meng, G
    Suryadevara, U
    Elias, L
    [J]. INVESTIGATIONAL NEW DRUGS, 2002, 20 (04) : 389 - 393
  • [3] A Phase II Study of Thalidomide in Advanced Metastatic Renal Cell Carcinoma
    David R. Minor
    Dana Monroe
    Lisa A. Damico
    Gloria Meng
    Uma Suryadevara
    Laurence Elias
    [J]. Investigational New Drugs, 2002, 20 : 389 - 393
  • [4] Phase II study of lenalidomide in patients (pts.) with metastatic renal cell carcinoma (MRCC).
    Choueiri, T. K.
    Dreicer, R.
    Rini, B. I.
    Elson, P.
    Garcia, J.
    Mekhail, T.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 226S - 226S
  • [5] Phase II study of interferon and thalidomide in metastatic renal cell carcinoma.
    Tripathi, RR
    Patel, B
    Heilbrun, L
    Hussain, M
    Flaherty, L
    Vaishampayan, UN
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 434S - 434S
  • [6] Randomized phase II study comparing thalidomide with medroxyprogesterone acetate in patients with metastatic renal cell carcinoma
    Lee, CP
    Patel, PM
    Selby, PJ
    Hancock, BW
    Mak, I
    Pyle, L
    James, MG
    Beirne, DA
    Steeds, S
    A'Hern, R
    Gore, ME
    Eisen, T
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (06) : 898 - 903
  • [7] Phase-II trial of thalidomide for patients with metastatic renal cell carcinoma (RCC).
    Green, D
    Meza-Junco, J
    Arce, C
    Chavez-Macgregor, M
    de la Peña, R
    Sotomayor, M
    Gabilondo, F
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 443S - 443S
  • [8] Phase I/II study of axitinib (axi) and nivolumab (nivo) in patients with metastatic renal cell carcinoma (mRCC).
    Zibelman, Matthew R.
    Geynisman, Daniel M.
    Molina, Ana M.
    Malizzia, Lois
    Devarajan, Karthik
    Luong, Diana
    Sullivan, Elizabeth
    Carducci, Michael Anthony
    Plimack, Elizabeth R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [9] A phase II study of intermittent sunitinib in previously untreated patients (pts) with metastatic renal cell carcinoma (mRCC).
    Wood, Laura S.
    Dreicer, Robert
    Garcia, Jorge A.
    Gilligan, Timothy D.
    Ali, Khaled B.
    Haddad, Housam
    Shah, Shetal N.
    Elson, Paul
    Rini, Brian I.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [10] Phase II trial of interferon and thalidomide in metastatic renal cell carcinoma
    Vaishampayan, Ulka N.
    Heilbrun, Lance K.
    Shields, Anthony F.
    Lawhorn-Crews, Jawana
    Baranowski, Karen
    Smith, Daryn
    Flaherty, Lawrence E.
    [J]. INVESTIGATIONAL NEW DRUGS, 2007, 25 (01) : 69 - 75
12345